Amoéba launches a massive new field trials campaign for 2021
Chassieu (France), April 6, 2021 - 8.30 am- AMOEBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating the risk in water and
human wounds, and of a biocontrol product for plant protection, still in a
development phase, announces within the development of its biofungicide active
substance, the lysate of the amoeba Willaertia magna C2c Maky, that it extends
its collaborations with its partners (PHILAGRO and STÄHLER) and other major
actors of the plant protection sector (BASF - BAYER - EVERGREEN GARDEN CARE -
GOWAN - KWIZDA).
Continued experimentation with partners
PHILAGRO (France) and STÄHLER (Switzerland), the partner companies with which
AMOÉBA has already signed term sheets that will lead to the signature of
distribution agreements on grapevines(1), will continue their experiments on
grapevines but also on other crops.
Biocontrol application tested on other crops and geographical areas
Other agrochemical players, some of whom have already conducted tests in 2020,
have decided to take part in this new field trials campaign. BASF - BAYER -
EVERGREEN GARDEN CARE - GOWAN - KWIZDA will test the active substance of AMOEBA
in different countries and on a wide range of crops (including vines, cereals
With the trials carried out by AMOÉBA itself, a total of more than 200 trials
are planned throughout the world (Europe, the Americas, Asia) in 2021. This
very large campaign will enable us to deepen our knowledge of the active
substance, compare several formulations, broaden our knowledge of the spectrum
of activity and generate, in Europe, results that will be used in future
marketing authorization applications for formulated biocontrol products.
"This new field trials campaign, in which new agrochemical players will take
part, demonstrates the need to act quickly to find alternatives to chemicals.
Today's agriculture, faced with more and more restrictions on the use of plant
protection products, has to take up many environmental challenges to meet the
expectations of the market and consumers. With 200 trials scheduled, including
more than 70 of its own, AMOEBA and its partners are determined to support all
the players in the agricultural world in order to bring about a genuine
agro-ecological transition", says Fabrice PLASSON, President and CEO of
(1) See press releases of December 9 and 18, 2020
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.
(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by AMOEBA.
The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.
Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 311 578,38 ?
RCS Lyon 523 877 21